Seth Harrison has invested in life sciences since 1991. He is the founder and managing partner of Apple Tree Partners, and Chairman of ATP companies Braeburn Pharmaceuticals, Limelight Bio, and Stoke Therapeutics. Prior to Founding ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds.
Seth’s prior investments include Aileron Therapeutics, ArQule, Ceolacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Syntimmune, Novus Therapeutics, Ultracision, and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides.
Seth received an AB from Princeton University, an MD and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.
Seth has current board responsibilities with Akero Therapeutics, Braeburn Pharmaceuticals, Corvidia Therapeutics, Elstar Therapeutics, Limelight Bio, and Stoke Therapeutics.